Currently, several ADC targets exist (TROP2, mesotheline, CEACAM5, DLL3, folate receptor alpha, guanylatcyclase, glycoprotein NMB, CD56, CD70 and CD138) with ADC compounds being tested in other cancer entities whose expression level in cervical cancer is of clinical interest. Here, TACSTD2 is linked to cancer.